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Abstract We describe a 5-year-old girl with marked hypoto-
nia, poor feeding and reduced facial expression since birth.
Congenital myopathy was suspected; muscle biopsy showed
unspecific type 1 fibre predominance. The possibility of a
ryanodine receptor 1 gene (RYR1)-associated myopathy was
considered, but not further investigated. At the age of 2 years,
she presented with exophthalmos. Brain MRI revealed optic
pathway glioma. On clinical examination, she had six café-
au-lait spots, thus fulfilling the diagnostic criteria for neurofi-
bromatosis type 1 (NF1). The hypotonia was then attributed to
NF1. At the age of 3 years, she developed scoliosis and had an
unusually severe motor delay for NF1, as she was not able to
walk independently. Dual pathology was suspected, and muscle
MRI showed the typical pattern for RYR1-related myopathy.
This was genetically confirmed with the discovery of two
heterozygous mutations. Conclusion: NF1 is one of the most
frequent genetic diseases in children. RYR1-related myopathy is
one of the most frequent causes of congenital myopathy. The
combination of these two pathologies has not yet been de-
scribed. In cases of unusual presentations or clinical course,
the possibility of genetic “double trouble” should be considered.
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Abbreviation
NF1 Neurofibromatosis type 1
RYR1 Ryanodine receptor 1
Introduction
Neurofibromatosis type 1 (NF1) (OMIM 613113, cytogenetic
location on chromosome 17q11.2) is one of the most frequent
inherited diseases in childhood with a birth prevalence of
1:3,000. The diagnosis is based on family history and clinical
findings [2, 14]. In infancy, hypotonia and developmental
delay are often among the first symptoms [7]. Ryanodine
receptor 1 gene (RYR1; OMIM 180901, cytogenetic location
19q13.2)-related myopathies are probably the most frequent
forms of congenital myopathies with an estimated prevalence
of 1:90,000 [8]. Typical central core disease and malignant
hyperthermia are usually dominantly inherited, but in recent
years, recessively inherited RYR1-related myopathies have
been increasingly recognised [6]. The typical clinical mani-
festation in childhood consists of relatively stable proximal,
axial and often facial weakness. More generalised weakness
and involvement of extraocular muscles have been described
in patients with recessive mutations. Orthopaedic complica-
tions such as dislocation of the hip, scoliosis and joint laxity
are frequent.
The combination of NF1 and RYR1-related myopathy has
not been described before.
Case report This 5-year-old girl was born at term by caesar-
ean section due to transversal position after an uneventful
pregnancy. Her mother and older brother are healthy; the
father is affected by ankylosing spondylitis. The girl adapted
with an APGAR 1/5/5. Because of respiratory insufficiency
and bradycardia, she was resuscitated and ventilated for
2 days. After 5 days, breathing was sufficient, except for rare
obstructive apnoeic episodes due to secretion. She had re-
duced spontaneous movements and facial expression, absent
tendon reflexes and reduced muscle tone. Anti-gravity move-
ments were not full. Prader-Willi syndrome, spinal muscular
atrophy and myotonic dystrophy were excluded by genetic
investigation. Brain magnetic resonance imaging (MRI), cre-
atine kinase, metabolic screening tests, electroencephalogra-
phy and nerve conduction studies of the tibial nerve were
normal. Because of persistent poor feeding at the age of
3 months, a gastrostomy was placed and a muscle biopsy of
the quadriceps femoris was performed, which showed vari-
ability of fibre size and type 1 fibre predominance and atrophy
(Fig 1a, b, c). She was discharged at the age of 4 months. At
age of 12months, she was able to sit independently and started
to mouth feed. Cognitive development was mildly delayed. At
the age of 21 months, she presented with strabismus, exoph-
thalmos and 6 café-au-lait spots. Brain MRI revealed bilateral
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Fig. 1 Biopsy from the quadriceps muscles (a Gomori trichrome) show-
ing variation in fibre size, mild endomysial fibrosis (arrow) and (b
NADH) fibre-type uniformity, but no cores and c numerous fibres ex-
pressing neonatal myosin (small dark fibres, see arrow). dMuscleMRI of
the upper leg: selected involvement of adductor magnus (AD of schematic
image), sartorius (S), vastus lateralis (VL), vastus intermedius (VIM),
vastus medialis (VM), spared rectus femoris (RF), adductor longus (AD)
and gracilis (G). e Schematic axial image of left upper and lower leg. f
Muscle MRI of lower leg: most affected muscle is soleus (SO), followed
by the lateral head of the gastrocnemius (GM)
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optic pathway glioma. The diagnostic criteria for NF1 were
thus fulfilled. Because of good visual function, the optic
pathway glioma was left untreated. The marked motor delay
with hypotonia was interpreted as within the limits of a severe
NF1 phenotype. She learned to sit up by herself, started to
shuffle, but was still not able to stand or crawl. Oral feeding
was sufficient to remove gastrostomy. At age of 3 years, she
developed freckling as an additional criterion for NF1 and a
rapidly progressive thoracic-lumbar scoliosis. Spinal MRI
failed to reveal vertebral dysplasia or spinal neurofibroma.
The possibility of an additional neuromuscular disorder was
re-evaluated. On neurological examination, proximal and fa-
cial weaknesses were noted, next to the known hypotonia.
Muscle MRI showed symmetrical signal change of vasti,
adductor magnus, gastrocnemius and soleus muscles. Rectus
femoris, adductor longus, gracilis and the peroneal group
muscles were relatively spared (Fig.1d, e). This pattern is
suggestive for RYR1-related myopathy. Full gene sequencing
revealed two novel variants (c.11360-1_11374del16, predict-
ed to remove the splice acceptor site at the start of exon 80;
c.14928C>G; p.Phe4976Leu, a point mutation at a position
that is highly conserved). Pathogenicity was assessed using
bioinformatics software Alamut v2.0. Both unaffected parents
carried one mutation (c.11360-1_11374del16 was inherited
from the father, c.14928C>G from the mother); therefore,
recessive inheritance is suggested.
Discussion
Our case demonstrates the difficulty of discerning hypotonia
due to a central problem as in NF1 fromweakness caused by a
neuromuscular disease in the first few years of life. Even
though a myopathy was suspected initially, this differential
consideration was rejected at the time when the diagnosis of
NF1 was confirmed. The marked motor difficulties and hypo-
tonia were then attributed to a severe NF1 phenotype. Of note,
hypotonia, facial dysmorphic features, scoliosis, joint laxity
and cognitive impairment have been described in patients with
large deletions in the NF1 region [9]. We did not perform
genetic testing of NF1 because our patient fulfilled the clinical
diagnostic criteria and developed freckling in addition. The
differential diagnosis of Legius syndrome (SPRED1; OMIM
611431) was not considered a possibility, because patients
with Legius syndrome do not develop optic pathway gliomas
[10]. On follow up, the progress in motor development was
poor and could not be attributed to hypotonia alone, but was
caused by additional proximal weakness. Therefore, the clin-
ical suspicion of an additional underlying congenital myopa-
thy was re-evaluated.
Congenital myopathies are group of neuromuscular dis-
eases with early onset, defined by the predominant
histopathological features and structural abnormalities. With
recent advances in molecular genetics, it has become clear that
different genetic congenital myopathies can share clinical and
pathological findings and that many individuals with a genet-
ically confirmed congenital myopathy have only non-specific
histopathological features. Cores as the classical histopatho-
logical finding of RYR1-related myopathies may be absent,
and unspecific findings such as fibre-type uniformity or type 1
fibre predominance are frequent, as in our patient. Muscle
MRI has been shown to be a helpful tool in the evaluation
of congenital myopathies [1, 5]. The typical selective pattern
of muscle involvement in RYR1-related myopathies led to the
genetic investigation in our patient. Two novel mutations were
detected; one is a splice site mutation and therefore predicted
to be pathogenic. The second variant is a point mutation at a
highly conserved position, but the physicochemical difference
between the amino acids is low. This mutation has not been
reported as a benign polymorphism so far, suggesting a dis-
ease causing role in this patient. Since the introduction of
diagnostic sequencing of the whole RYR1 gene, many novel
mutations have been detected but assigning pathogenicity is
often difficult [6].
The combination of two different genetic diseases has been
reported in a few case reports of patients with different neu-
romuscular disorders, where the combination led to a more
severe or unusual phenotype [3, 4, 11–13].
Conclusion
In an unusually severe or atypical presentation, “double trou-
ble” should be suspected. In our patient, careful clinical re-
evaluation led to further investigations that ultimately led to
the two diagnoses. NF1 is one of the most common genetic
diseases in child neurology; the combination with another
disorder is therefore a possibility. The diagnosis of the
RYR1-relatedmyopathy has important implications for genetic
counselling and clinical management regarding the risk of
malignant hyperthermia for the patient and the family.
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